Trial reportJournal of clinical hypertension (Greenwich, Conn.)2008
Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Narrative update of clinical trials with antihypertensive drugs in children and adolescents.Frontiers in cardiovascular medicine · 2022Pooled it
- Hypertension in Children and Adolescents: A Position Statement From a Panel of Multidisciplinary Experts Coordinated by the French Society of Hypertension.Frontiers in pediatrics · 2021Pooled it
- Pharmacological interventions for hypertension in children.The Cochrane database of systematic reviews · 2014Pooled it
- Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study.Clinical and experimental nephrology · 2022Trial
- Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study.Advances in therapy · 2018Trial
- Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.Paediatric drugs · 2012Trial
- Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension: profile report.Paediatric drugs · 2012Trial
- Clinical guidelines for the diagnosis, evaluation, and management of hypertension for Korean children and adolescents: the Korean Working Group of Pediatric Hypertension.Kidney research and clinical practice · 2025Article
- Prevalence of Diabetic Foot Ulcer and Determinant Factors Among Adult Diabetic Patients Who Attend the Diabetic Follow-Up at Adwa General Hospital, Ethiopia, 2019: A Cross-Sectional Study.Health science reports · 2024Article
- Blood Pressure Tracking From Childhood to Adulthood.Frontiers in pediatrics · 2021Review
- Antihypertensive agents: a long way to safe drug prescribing in children.Pediatric nephrology (Berlin, Germany) · 2020Review
- Research Gaps in Primary Pediatric Hypertension.Pediatrics · 2019Review
- Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.Journal of the American Heart Association · 2018Article
- Screening children for hypertension: the case against.Pediatric nephrology (Berlin, Germany) · 2018Review
- Prolonged Postoperative Vasoplegia in Pediatric Patients on Chronic Angiotensin II Blocker Treatment.Frontiers in cardiovascular medicine · 2018Article
- Pharmacologic Treatment of Pediatric Hypertension.Current hypertension reports · 2016Review
- Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults.European journal of clinical pharmacology · 2016Article
- Anti-hypertensive drugs in children and adolescents.World journal of cardiology · 2014Review
- Update on the pharmacologic treatment of hypertension in pediatrics.Journal of clinical hypertension (Greenwich, Conn.) · 2012Review
- Pediatric cardiovascular drug trials, lessons learned.Journal of cardiovascular pharmacology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This 4-week randomized, double blind, placebo-controlled study (N=240), 1-year open label trial (N=233), and single-dose pharmacokinetic study (N=22) evaluated candesartan cilexetil (3 doses) in hypertensive children aged 6 to 17 years. Seventy-one percent were 12 years of age or older, 71% were male, and 47% were black. Systolic (SBP)/diastolic (DBP) blood pressure declined 8.6/4.8-11.2/8.0 mm Hg with candesartan and 3.7/1.8 mm Hg with placebo (P<.01 compared to placebo for SBP and for the mid and high doses for DBP; placebo-corrected 4.9/3.0-7.5/6.2 mm Hg). The slopes for dose were not, however, different from zero (P>.05). The response rate (SBP and DBP <95th percentile) after 1 year was 53%. The pharmacokinetic profiles in 6- to 12- and 12- to 17-year-olds were similar and were comparable to adults. Eight candesartan patients discontinued treatment because of an adverse event. Candesartan is an effective, well-tolerated antihypertensive agent for children aged 6 to 17 years and has a pharmacokinetic profile that is similar to that in adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.